$CTSO
Cytosorbents Corp Stock $ctso

$ctso Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000114420416132102 Filed on November 07, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$3.084M	$2.412M	$1.344M
YoY Change	75.11%	79.49%	15.6%
Cost Of Revenue	$1.300M	$963.9K	$638.8K
YoY Change	62.5%	50.88%	34.24%
Gross Profit	$1.787M	$1.448M	$704.8K
YoY Change	86.65%	105.43%	2.67%
Gross Profit Margin	57.94%	60.03%	52.45%
Selling, General & Admin	$4.690M	$2.141M	$1.700M
YoY Change	97.89%	25.91%	37.04%
% of Gross Profit	262.52%	147.85%	241.21%
Research & Development	$1.660M	$1.172M	$866.3K
YoY Change	32.8%	35.3%	-1.59%
% of Gross Profit	92.92%	80.96%	122.92%
Depreciation & Amortization	$50.00K	$40.00K	$40.00K
YoY Change	66.67%	0.0%	100.0%
% of Gross Profit	2.8%	2.76%	5.68%
Operating Expenses	$6.350M	$3.592M	$2.855M
YoY Change	75.41%	25.81%	31.57%
Operating Profit	-$4.570M	-$2.144M	-$2.150M
YoY Change	106.41%	-0.28%	44.94%
Interest Expense	-$650.0K	-$117.4K	$3.190K
YoY Change	-291.18%	-3778.75%	-106.85%
% of Operating Profit
Other Income/Expense, Net		-$43.91K	-$697.1K
YoY Change		-93.7%	4611.39%
Pretax Income	-$5.220M	-$2.188M	-$2.847M
YoY Change	124.03%	-23.15%	90.04%
Income Tax	-$320.0K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.910M	-$2.188M	-$2.847M
YoY Change	145.5%	-23.15%	90.04%
Net Earnings / Revenue	-159.23%	-90.73%	-211.92%
Basic Earnings Per Share			-$0.11
Diluted Earnings Per Share	-$192.8K	-$86.08K	-$0.11
COMMON SHARES
Basic Shares Outstanding	25.47M shares	25.44M shares	25.05M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.200M	$6.400M	$9.300M
YoY Change	-30.67%	-31.18%	19.23%
Cash & Equivalents	$5.245M	$6.375M	$7.386M
Short-Term Investments		$0.00	$1.900M
Other Short-Term Assets	$300.0K	$200.0K	$400.0K
YoY Change	-40.0%	-50.0%	100.0%
Inventory	$834.0K	$1.100M	$1.300M
Prepaid Expenses
Receivables	$1.433M	$1.400M	$553.4K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$7.828M	$9.100M	$11.60M
YoY Change	-20.61%	-21.55%	29.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$569.4K	$600.0K	$500.0K
YoY Change	2.17%	20.0%	161.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.296M	$1.200M	$700.0K
YoY Change	54.89%	71.43%	45.53%
Total Long-Term Assets	$1.865M	$1.800M	$1.200M
YoY Change	33.81%	50.0%	78.53%
TOTAL ASSETS
Total Short-Term Assets	$7.828M	$9.100M	$11.60M
Total Long-Term Assets	$1.865M	$1.800M	$1.200M
Total Assets	$9.694M	$10.90M	$12.80M
YoY Change	-13.87%	-14.84%	32.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.330M	$700.0K	$500.0K
YoY Change	94.28%	40.0%	12.07%
Accrued Expenses	$44.88K	$1.500M	$800.0K
YoY Change	-93.59%	87.5%	100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$833.3K	$416.7K
YoY Change
Total Short-Term Liabilities	$4.278M	$5.000M	$3.400M
YoY Change	40.55%	47.06%	119.43%
LONG-TERM LIABILITIES
Long-Term Debt	$4.078M	$4.480M	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$4.078M	$4.480M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.278M	$5.000M	$3.400M
Total Long-Term Liabilities	$4.078M	$4.480M	$0.00
Total Liabilities	$8.356M	$9.479M	$3.400M
YoY Change	174.54%	178.8%	126.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$143.5M
YoY Change	8.29%
Common Stock	$25.48K
YoY Change	0.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.337M	$1.400M	$9.400M
YoY Change
Total Liabilities & Shareholders Equity	$9.694M	$10.90M	$12.80M
YoY Change	-13.87%	-14.84%	32.96%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$4.910M	-$2.188M	-$2.847M
YoY Change	145.5%	-23.15%	90.04%
Depreciation, Depletion And Amortization	$50.00K	$40.00K	$40.00K
YoY Change	66.67%	0.0%	100.0%
Cash From Operating Activities	-$1.080M	-$2.470M	-$2.260M
YoY Change	-51.57%	9.29%	17.1%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	-$190.0K	-$180.0K
YoY Change	-54.55%	5.56%	200.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$250.0K	$1.240M
YoY Change	-100.0%	-79.84%	-147.69%
Cash From Investing Activities	-$90.00K	$60.00K	$1.060M
YoY Change	-80.85%	-94.34%	-139.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	50.00K	100.0K	560.0K
YoY Change	-91.67%	-82.14%	1766.67%
NET CHANGE
Cash From Operating Activities	-1.080M	-2.470M	-2.260M
Cash From Investing Activities	-90.00K	60.00K	1.060M
Cash From Financing Activities	50.00K	100.0K	560.0K
Net Change In Cash	-1.120M	-2.310M	-640.0K
YoY Change	-46.67%	260.94%	-86.0%
FREE CASH FLOW
Cash From Operating Activities	-$1.080M	-$2.470M	-$2.260M
Capital Expenditures	-$100.0K	-$190.0K	-$180.0K
Free Cash Flow	-$980.0K	-$2.280M	-$2.080M
YoY Change	-51.24%	9.62%	11.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	us-gaap	Liabilities Liabilities	3043779	USD
CY2016Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4479740	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2016Q3	us-gaap	Liabilities Liabilities	9479149	USD
CY2016Q3	us-gaap	Revenue From Grants RevenueFromGrants	268592	USD
CY2015Q3	us-gaap	Revenue From Grants RevenueFromGrants	272166	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	11987	USD
CY2016Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2015Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	3030622	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	2411708	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1343625	USD
	us-gaap	Gross Profit GrossProfit	1621880	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	1447827	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2656646	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1408742	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	638830	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3120347	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2619018	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1172155	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	866334	USD
CY2015Q3	us-gaap	Professional Fees ProfessionalFees	288722	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2140563	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1700035	USD
	us-gaap	Operating Expenses OperatingExpenses	8262771	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	3592039	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	2855091	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6921677	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6640891	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2144212	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2150296	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-111864	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	8842	USD
CY2016Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-117352	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	176096	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-315594	USD
CY2016Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	73445	USD
CY2015Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	70993	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	666815	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1071459	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25444565	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25037538	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25420650	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24812707	shares
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	5593235	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2548229	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	6444228	USD
	us-gaap	Gross Profit GrossProfit	3787582	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2143116	USD
CY2015Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3190	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	704795	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	963881	USD
	us-gaap	Professional Fees ProfessionalFees	853056	USD
	us-gaap	Professional Fees ProfessionalFees	802153	USD
CY2016Q3	us-gaap	Professional Fees ProfessionalFees	279321	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6735856	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4841600	USD
	us-gaap	Operating Expenses OperatingExpenses	10709259	USD
	us-gaap	Revenue From Grants RevenueFromGrants	470406	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
	us-gaap	Revenue From Grants RevenueFromGrants	850993	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-60820	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	510826	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-161593	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	218011	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6130065	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-211547	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	724025	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-817578	USD
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	494596	USD
CY2015Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	771328	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-602583	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-538503	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-697145	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7524260	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-6130065	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2682715	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2847441	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-49807	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7685853	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5912054	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2743535	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2897248	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7524260	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-2682715	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-2847441	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	598966	USD
	ctso	Stock Issued During Period Value Stock Cash Options Exercised StockIssuedDuringPeriodValueStockCashOptionsExercised	79990	USD
	ctso	Stock Issued During Period Value Stock Cash Warrants Exercised StockIssuedDuringPeriodValueStockCashWarrantsExercised	50000	USD
	ctso	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	0	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	125059	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	109395	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	78430	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	176096	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	260232	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	747117	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-237202	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-143200	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	769352	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-295516	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-322000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	21363	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	7134	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	862754	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-206763	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-833	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	155696	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	296362	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	341665	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	127848	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	2192000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	3936547	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	3935000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	1694639	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-422663	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	79990	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	363085	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	50000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1272424	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5011157	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	11044093	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	4293	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-18805	USD
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0	USD
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	9408584	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5651891	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6822314	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1058198	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3780311	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3605280	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7385591	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	118833	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Interest Paid InterestPaid	71233	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	ctso	Supplemental Noncash Transactions SupplementalNoncashTransactions	0	USD
	ctso	Supplemental Noncash Transactions SupplementalNoncashTransactions	903916	USD
CY2016Q3	ctso	Number Of Patents Issued NumberOfPatentsIssued	32	pure
CY2016Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	7318	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3275	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	382099	USD
CY2016Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	451614	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	758562	USD
CY2016Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	43694	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	50020	USD
	us-gaap	Advertising Expense AdvertisingExpense	153000	USD
	us-gaap	Advertising Expense AdvertisingExpense	200000	USD
CY2016Q3	us-gaap	Advertising Expense AdvertisingExpense	28000	USD
CY2015Q3	us-gaap	Advertising Expense AdvertisingExpense	84000	USD
	us-gaap	Freight Costs FreightCosts	98000	USD
CY2016Q3	us-gaap	Freight Costs FreightCosts	28000	USD
CY2015Q3	us-gaap	Freight Costs FreightCosts	32000	USD
CY2015Q3	ctso	Aggregate Registered Amount For Offerings AggregateRegisteredAmountForOfferings	100000000	USD
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	28880	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	225000	USD
CY2016Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.02
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.68
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.04
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	19757	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	121.85
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.17
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	25200	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1034219	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	500150	shares
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm	P3Y7M6D
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2477279	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2966391	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.92
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.56
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0124	pure
CY2014Q1	ctso	Fair Value Warrant Liability FairValueWarrantLiability	862920	USD
CY2014Q1	us-gaap	Share Price SharePrice	6.00
CY2015Q3	us-gaap	Share Price SharePrice	6.41
CY2016Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	736000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	566000	shares
CY2015Q2	ctso	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedInPeriodFairValue	1388000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	241000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	900100	shares
CY2016Q2	ctso	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedInPeriodFairValue	2437000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	72400	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	816000	shares
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1666667	USD
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1249999	USD
CY2016Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	5000000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0181	pure
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	794708	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	499650	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	206410	shares
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1122867	shares
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.72
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.71
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	3.3
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.04
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.54
CY2016Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	399000	USD
CY2015Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	736000	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	7.81
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	7.81
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.687	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0082	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y5M8D
CY2016Q3	us-gaap	Share Price SharePrice	6.4
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y5M8D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0102	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.723	pure
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1666667	USD
	ctso	License Period LicensePeriod	P18Y
CY2016Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	416667	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	0	USD
	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	15240	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, and valuation methods used to determine the fair value of the warrant liability.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Concentration of Credit Risk</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of September 30, 2016, two distributors accounted for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 31</font>% of outstanding grant and accounts receivable. At December 31, 2015, three distributors accounted for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 48</font>% of outstanding grant and accounts receivable. For the nine months ended September 30, 2016, one direct customer accounted for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% of the Company’s total revenue. No other agency, distributor, or direct customer represented more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the Company’s revenue. For the nine months ended September 30, 2015, approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 16</font>% of revenues were from one U.S. government grant agency. No other agency, distributor, or direct customer represented more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the Company’s revenue. For the three months ended September 30, 2016, one direct customer accounted for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% of the Company’s total revenue. No other agency, distributor, or direct customer represented more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the Company’s revenue. For the three months ended September 30, 2015, no agency, distributor, or direct customer represented more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the Company’s revenue.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	556340	USD
CY2016Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	103593	USD
CY2016Q3	us-gaap	Long Term Debt LongTermDebt	4896407	USD
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	416667	USD
CY2016Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1092166	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	CTSO
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25468966	shares
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	Cytosorbents Corp
	dei	Entity Central Index Key EntityCentralIndexKey	0001175151
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q3	ctso	Number Of Countries In Which Product Marketed NumberOfCountriesInWhichProductMarketed	40	pure
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><b> <font style="FONT-SIZE: 10pt">1.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><b> <font style="FONT-SIZE: 10pt">BASIS OF PRESENTATION</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The <font style="WIDOWS: 2; TEXT-TRANSFORM: none; FONT-STYLE: normal; TEXT-INDENT: 0px; LETTER-SPACING: normal; DISPLAY: inline !important; FONT-FAMILY: 'Times New Roman', Times, serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; COLOR: rgb(0,0,0); FONT-SIZE: 13px; FONT-WEIGHT: normal; WORD-SPACING: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> interim financial statements of CytoSorbents Corporation (the “Company”, “we” or “our”) have been prepared in conformity with</font> accounting principles generally accepted in the United States of America (U.S. GAAP). In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December  31, 2015 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 9, 2016. The results for the three and nine months ended September 30, 2016 and 2015 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of September 30, 2016, the Company had an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(140,050,118)</font>, which included net losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(7,524,260)</font> for the nine months ended September 30, 2016 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(6,130,065)</font> for the nine months ended September 30, 2015. The Company’s losses have resulted principally from costs incurred in the research and development of the Company’s polymer technology and selling, general and administrative expenses. The Company intends to continue to conduct significant additional research, development, and clinical study activities which, together with expenses incurred for the establishment of manufacturing arrangements and a marketing and distribution presence and other selling, general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability is uncertain. The Company’s ability to achieve profitability will depend, among other things, on successfully completing the development of the Company’s technology and commercial products, obtaining additional requisite regulatory approvals in markets not covered by the CE Mark previously received and for potential label extensions of the Company’s current CE Mark, establishing manufacturing and sales and marketing arrangements with third parties, and raising sufficient funds to finance the Company’s activities. No assurance can be given that the Company’s product development efforts will be successful, that the Company’s current CE Mark will enable the Company to achieve profitability, that additional regulatory approvals in other countries will be obtained, that any of the Company’s products will be manufactured at a competitive cost and will be of acceptable quality, or that the Company will be able to achieve profitability or that profitability, if achieved, can be sustained. These matters raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments related to the outcome of this uncertainty.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name	View Source	Status
0001144204-16-132102-index-headers.html	Edgar Link	pending
0001144204-16-132102-index.html	Edgar Link	pending
0001144204-16-132102.txt	Edgar Link	pending
0001144204-16-132102-xbrl.zip	Edgar Link	pending
ctso-20160930.xml	Edgar Link	completed
ctso-20160930.xsd	Edgar Link	pending
ctso-20160930_cal.xml	Edgar Link	unprocessable
ctso-20160930_def.xml	Edgar Link	unprocessable
ctso-20160930_lab.xml	Edgar Link	unprocessable
ctso-20160930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v451479_10q.htm	Edgar Link	pending
v451479_ex31-1.htm	Edgar Link	pending
v451479_ex31-2.htm	Edgar Link	pending
v451479_ex32-1.htm	Edgar Link	pending
v451479_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTSO
Cytosorbents Corp Stock $ctso

2016 Q4 Form 10-Q Financial Statement

#000114420416132102 Filed on November 07, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO Cytosorbents Corp Stock $ctso

2016 Q4 Form 10-Q Financial Statement

#000114420416132102 Filed on November 07, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO
Cytosorbents Corp Stock $ctso